Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.68 |
| ▸ | HTR7 | P34969 | 10/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7258387 | 0.91 | KMO (0.57) | KMOHTR7MCL1HTR6 | |
| SCHEMBL29758270 | 0.88 | KMO (0.56) | KMOHTR7LMNATBXAS1MCL1 | |
| SCHEMBL19100386 | 0.88 | KMO (0.56) | KMOHTR7LMNATBXAS1MCL1 | |
| SCHEMBL26683806 | 0.84 | KMT2A (0.60) | KMOHTR7FGFR1FGFR4 | |
| SCHEMBL23631621 | 0.82 | KMO (0.48) | KMOHTR7MCL1HTR6FGFR1 | |
| SCHEMBL31444682 | 0.82 | HTR7 (0.48) | KMOHTR7LMNAHTR6FGFR1 | |
| Fumaric Acid SCHEMBL7677266 | 0.81 | KMO (0.47) | KMOHTR7LMNAHTR6FGFR1 | |
| SCHEMBL10253582 | 0.81 | KMO (0.68) | KMOHTR7LMNAMCL1 | |
| SCHEMBL31121493 | 0.80 | HTR7 (0.54) | KMOHTR7HTR6FGFR1FGFR4 | |
| SCHEMBL5621531 | 0.80 | HTR7 (0.54) | KMOHTR7HTR6FGFR1FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | RARA, RARG, RARB | KMO 1891/4885HTR7 3905/4885LMNA 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.